Quantcast
Home > Quotes > AVRO

AVROBIO, Inc. Common Stock (AVRO) Quote & Summary Data

AVRO 
$14.38
*  
1.13
7.29%
Get AVRO Alerts
*Delayed - data as of Jun. 26, 2019  -  Find a broker to begin trading AVRO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
40
Today's High / Low
$ 16 / $ 14.31
Share Volume
90,877
50 Day Avg. Daily Volume
118,252
Previous Close
$ 15.51
52 Week High / Low
$ 53.70 / $ 11.845
Market Cap
347,234,220
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -4.86
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-1.56

Intraday Chart

Shares Traded

Share Volume:
90,877
50 Day Avg. Daily Volume:
118,252

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -4.86

Trading Range

The current last sale of $14.38 is 21.40% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 16 $ 53.70
 Low: $ 14.31 $ 11.845

Company Description (as filed with the SEC)

We are a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Our gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. We believe that our approach, which is designed to transform stem cells from patients into therapeutic products, has the potential to provide curative benefit for a range of diseases. Our initial focus is on a group of rare genetic diseases referred to as lysosomal storage diseases, some of which today are primarily managed with enzyme replacement therapies, or ERTs.  ... More ...  



Risk Grade

Where does AVRO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 15.61
Open Date:
Jun. 26, 2019
Close Price:
$ 14.38
Close Date:
Jun. 26, 2019


Consensus Recommendation

Analyst Info